| __timestamp | Alnylam Pharmaceuticals, Inc. | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 60716000 |
| Thursday, January 1, 2015 | 60610000 | 119401000 |
| Friday, January 1, 2016 | 89354000 | 140879000 |
| Sunday, January 1, 2017 | 199365000 | 199243000 |
| Monday, January 1, 2018 | 382359000 | 240636000 |
| Tuesday, January 1, 2019 | 479005000 | 264359000 |
| Wednesday, January 1, 2020 | 588420000 | 260583000 |
| Friday, January 1, 2021 | 620639000 | 324951000 |
| Saturday, January 1, 2022 | 770658000 | 372766000 |
| Sunday, January 1, 2023 | 795646000 | 378378000 |
| Monday, January 1, 2024 | 975526000 | 396826000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and profitability. Over the past decade, Alnylam Pharmaceuticals and Bio-Techne Corporation have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive expansion strategy. In contrast, Bio-Techne's expenses grew by approximately 520%, indicating a more measured approach.
While Alnylam's expenses peaked in 2023, Bio-Techne continued its steady climb, with 2024 projections showing a further increase. This divergence highlights the strategic choices each company makes in balancing growth with cost efficiency. As investors and industry watchers analyze these trends, the question remains: which strategy will yield better long-term returns?
Explore the data to uncover how these biotech giants navigate the complexities of SG&A management.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Evotec SE